Companies: 10,795·Total market cap: $144.5T
Barinthus Biotherapeutics plc

Barinthus Biotherapeutics plc

BRNSNASDAQHealthcare● Active
$0.74
+$0.02(+2.49%)
Market Cap$30142398
P/E Ratio
52W High$2.92
52W Low$0.512
Overview

Barinthus Biotherapeutics plc (BRNS) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · BRNS · as of Jun 9, 2026

Key Statistics

EPS (TTM)$-1.29brns eps ttm · brns earnings per shareEarnings history
PE Ratio (TTM)brns pe ratio ttm · brns price to earningsPE Ratio deep dive
Revenue (TTM)0.00brns revenue ttm · brns annual revenueFull revenue history
Dividend YieldNo Dividenddoes brns pay dividends · brns dividend yieldDividend history
Shares Outstanding40.5Mbrns shares outstanding · brns floatShares outstanding history
Next EarningsAug 6, 2026Est.brns earnings date · brns next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$0.00▼ 100.00% YoY
202320242025
barinthus biotherapeutics plc revenue · brns revenue 2025
FY 2025Net Income-$66.6M▼ 9.02% YoY
202320242025
barinthus biotherapeutics plc net income · brns profit 2025
FY 2025EPS$-1.64▼ 5.81% YoY
202320242025
brns eps · barinthus biotherapeutics plc earnings per share 2025
TTM:Revenue: $0.00Net Income: -$52.3MEPS: $-1.29View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy4 analystsis brns a buy · brns analyst rating
Strong Buy
0
Buy
3
Hold
1
Sell
0
Strong Sell
0
12-Month Price Target
$3.00Low
$0.74Current
$3.00Avg Target306.56% upside
$3.00High
brns price target · brns 12 month forecast

Total: 4 · Buy rate: 75.0%

The BRNS analyst consensus is Buy, based on ratings from 4 Wall Street analysts over the past 3 months. The average 12-month price target is $3.00, representing +306.56% upside from the current price of $0.74.

Stock Performance

Full History
1D+10.41%
1W+2.71%
1M+7.46%
3M+28.09%
YTD+2.84%
1Y-27.30%
5Y-95.34%

About Barinthus Biotherapeutics plc

CEOWilliam James Enright
IPO DateApr 30, 2021
Employees105
CountryGB

Barinthus Biotherapeutics plc a clinical-stage biopharmaceutical firm, is dedicated to pioneering innovative T-cell immunotherapies. These cutting-edge treatments are engineered to harness the body's…

what is barinthus biotherapeutics plc · brns stock overview · barinthus biotherapeutics plc company profile · who is barinthus biotherapeutics plc ceo · brns NASDAQ · barinthus biotherapeutics plc headquarters · barinthus biotherapeutics plc business segments

About Stock Overview & Key Data

Barinthus Biotherapeutics plc (BRNS) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Apr 30, 2021. As of the latest trading session, BRNS stock price is $0.74, with a market capitalization of $30.1M. The stock has returned -27.30% over the past 12 months and +2.84% year-to-date.

According to 4 Wall Street analysts, the consensus rating for Barinthus Biotherapeutics plc stock is Buy, with an average 12-month price target of $3.00. In fiscal year 2025, Barinthus Biotherapeutics plc reported revenue of — and net income of -$66.6M. For detailed data — including Barinthus Biotherapeutics plc revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Barinthus Biotherapeutics plc (BRNS) stock price is $0.74. The stock is traded on NASDAQ under the ticker symbol BRNS. The 52-week range is $0.51 – $2.92.

BRNS stock priceBRNS quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice